AustralieFrV1, Main, Exploration, bibRecord, 001042

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Identifieur interne : 001042 ( Main/Exploration ); précédent : 001041; suivant : 001043

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Auteurs : Meletios A. Dimopoulos [Grèce] ; Hartmut Goldschmidt [Allemagne] ; Ruben Niesvizky [États-Unis] ; Douglas Joshua [Australie] ; Wee-Joo Chng [Singapour] ; Albert Oriol [Espagne] ; Robert Z. Orlowski [États-Unis] ; Heinz Ludwig [Autriche] ; Thierry Facon [France] ; Roman Hajek [République tchèque] ; Katja Weisel [Allemagne] ; Vania Hungria [Brésil] ; Leonard Minuk [Canada] ; Shibao Feng [États-Unis] ; Anita Zahlten-Kumeli [États-Unis] ; Amy S. Kimball [États-Unis] ; Philippe Moreau [France]

Source :

The Lancet. Oncology [ 1474-5488 ] ; 2017.

RBID : pubmed:28843768

Descripteurs français

English descriptors

KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Bortezomib (administration & dosage), Bortezomib (adverse effects), Cause of Death, Dexamethasone (administration & dosage), Dexamethasone (adverse effects), Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Internationality, Kaplan-Meier Estimate, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma (drug therapy), Multiple Myeloma (mortality), Multiple Myeloma (pathology), Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (mortality), Neoplasm Recurrence, Local (pathology), Oligopeptides (administration & dosage), Oligopeptides (adverse effects), Prognosis, Proportional Hazards Models, Prospective Studies, Survival Analysis, Treatment Outcome.
MESH :
- chemical , administration & dosage : Bortezomib, Dexamethasone, Oligopeptides.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Dexamethasone, Oligopeptides.
- drug therapy : Multiple Myeloma, Neoplasm Recurrence, Local.
- mortality : Multiple Myeloma, Neoplasm Recurrence, Local.
- pathology : Multiple Myeloma, Neoplasm Recurrence, Local.
- Adult, Aged, Cause of Death, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Internationality, Kaplan-Meier Estimate, Male, Maximum Tolerated Dose, Middle Aged, Prognosis, Proportional Hazards Models, Prospective Studies, Survival Analysis, Treatment Outcome.

Abstract

The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups.

DOI: 10.1016/S1470-2045(17)30578-8
PubMed: 28843768

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.</title>
<author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name>
<affiliation wicri:level="3"><nlm:affiliation>School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece. Electronic address: mdimop@med.uoa.gr.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name>
<affiliation wicri:level="3"><nlm:affiliation>Heidelberg Medical University, Heidelberg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Heidelberg Medical University, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name>
<affiliation wicri:level="2"><nlm:affiliation>Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Joshua, Douglas" sort="Joshua, Douglas" uniqKey="Joshua D" first="Douglas" last="Joshua">Douglas Joshua</name>
<affiliation wicri:level="1"><nlm:affiliation>Royal Prince Alfred Hospital, Camperdown, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Prince Alfred Hospital, Camperdown, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chng, Wee Joo" sort="Chng, Wee Joo" uniqKey="Chng W" first="Wee-Joo" last="Chng">Wee-Joo Chng</name>
<affiliation wicri:level="1"><nlm:affiliation>National University Cancer Institute, National University Health System, Cancer Science Institute, Singapore; National University of Singapore, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>National University Cancer Institute, National University Health System, Cancer Science Institute, Singapore; National University of Singapore</wicri:regionArea>
<wicri:noRegion>Singapore; National University of Singapore</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Oriol, Albert" sort="Oriol, Albert" uniqKey="Oriol A" first="Albert" last="Oriol">Albert Oriol</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z" last="Orlowski">Robert Z. Orlowski</name>
<affiliation wicri:level="2"><nlm:affiliation>MD Anderson Cancer Center, University of Texas, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MD Anderson Cancer Center, University of Texas, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name>
<affiliation wicri:level="3"><nlm:affiliation>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name>
<affiliation wicri:level="3"><nlm:affiliation>CHRU Lille, Hôpital Claude Huriez, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHRU Lille, Hôpital Claude Huriez, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava</wicri:regionArea>
<wicri:noRegion>Ostrava</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weisel, Katja" sort="Weisel, Katja" uniqKey="Weisel K" first="Katja" last="Weisel">Katja Weisel</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitatsklinikum Tubingen, Tubingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Universitatsklinikum Tubingen, Tubingen</wicri:regionArea>
<wicri:noRegion>Tubingen</wicri:noRegion>
<wicri:noRegion>Tubingen</wicri:noRegion>
<wicri:noRegion>Tubingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hungria, Vania" sort="Hungria, Vania" uniqKey="Hungria V" first="Vania" last="Hungria">Vania Hungria</name>
<affiliation wicri:level="3"><nlm:affiliation>Santa Casa Medical School, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Santa Casa Medical School, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Minuk, Leonard" sort="Minuk, Leonard" uniqKey="Minuk L" first="Leonard" last="Minuk">Leonard Minuk</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Care Manitoba, Winnipeg, MB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Cancer Care Manitoba, Winnipeg, MB</wicri:regionArea>
<wicri:noRegion>MB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feng, Shibao" sort="Feng, Shibao" uniqKey="Feng S" first="Shibao" last="Feng">Shibao Feng</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zahlten Kumeli, Anita" sort="Zahlten Kumeli, Anita" uniqKey="Zahlten Kumeli A" first="Anita" last="Zahlten-Kumeli">Anita Zahlten-Kumeli</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimball, Amy S" sort="Kimball, Amy S" uniqKey="Kimball A" first="Amy S" last="Kimball">Amy S. Kimball</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name>
<affiliation wicri:level="3"><nlm:affiliation>Hematology Department, University of Nantes, Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hematology Department, University of Nantes, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28843768</idno>
<idno type="pmid">28843768</idno>
<idno type="doi">10.1016/S1470-2045(17)30578-8</idno>
<idno type="wicri:Area/PubMed/Corpus">000412</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000412</idno>
<idno type="wicri:Area/PubMed/Curation">000410</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000410</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000410</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000410</idno>
<idno type="wicri:Area/Ncbi/Merge">004D49</idno>
<idno type="wicri:Area/Ncbi/Curation">004D49</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004D49</idno>
<idno type="wicri:Area/Main/Merge">001037</idno>
<idno type="wicri:Area/Main/Curation">001042</idno>
<idno type="wicri:Area/Main/Exploration">001042</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.</title>
<author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name>
<affiliation wicri:level="3"><nlm:affiliation>School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece. Electronic address: mdimop@med.uoa.gr.</nlm:affiliation>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea>School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens</wicri:regionArea>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name>
<affiliation wicri:level="3"><nlm:affiliation>Heidelberg Medical University, Heidelberg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Heidelberg Medical University, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name>
<affiliation wicri:level="2"><nlm:affiliation>Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Joshua, Douglas" sort="Joshua, Douglas" uniqKey="Joshua D" first="Douglas" last="Joshua">Douglas Joshua</name>
<affiliation wicri:level="1"><nlm:affiliation>Royal Prince Alfred Hospital, Camperdown, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Prince Alfred Hospital, Camperdown, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chng, Wee Joo" sort="Chng, Wee Joo" uniqKey="Chng W" first="Wee-Joo" last="Chng">Wee-Joo Chng</name>
<affiliation wicri:level="1"><nlm:affiliation>National University Cancer Institute, National University Health System, Cancer Science Institute, Singapore; National University of Singapore, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>National University Cancer Institute, National University Health System, Cancer Science Institute, Singapore; National University of Singapore</wicri:regionArea>
<wicri:noRegion>Singapore; National University of Singapore</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Oriol, Albert" sort="Oriol, Albert" uniqKey="Oriol A" first="Albert" last="Oriol">Albert Oriol</name>
<affiliation wicri:level="3"><nlm:affiliation>Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona</wicri:regionArea>
<placeName><settlement type="city">Barcelone</settlement>
<region nuts="2" type="region">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z" last="Orlowski">Robert Z. Orlowski</name>
<affiliation wicri:level="2"><nlm:affiliation>MD Anderson Cancer Center, University of Texas, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>MD Anderson Cancer Center, University of Texas, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name>
<affiliation wicri:level="3"><nlm:affiliation>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name>
<affiliation wicri:level="3"><nlm:affiliation>CHRU Lille, Hôpital Claude Huriez, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>CHRU Lille, Hôpital Claude Huriez, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name>
<affiliation wicri:level="1"><nlm:affiliation>University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava</wicri:regionArea>
<wicri:noRegion>Ostrava</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weisel, Katja" sort="Weisel, Katja" uniqKey="Weisel K" first="Katja" last="Weisel">Katja Weisel</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitatsklinikum Tubingen, Tubingen, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Universitatsklinikum Tubingen, Tubingen</wicri:regionArea>
<wicri:noRegion>Tubingen</wicri:noRegion>
<wicri:noRegion>Tubingen</wicri:noRegion>
<wicri:noRegion>Tubingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hungria, Vania" sort="Hungria, Vania" uniqKey="Hungria V" first="Vania" last="Hungria">Vania Hungria</name>
<affiliation wicri:level="3"><nlm:affiliation>Santa Casa Medical School, São Paulo, Brazil.</nlm:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Santa Casa Medical School, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Minuk, Leonard" sort="Minuk, Leonard" uniqKey="Minuk L" first="Leonard" last="Minuk">Leonard Minuk</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Care Manitoba, Winnipeg, MB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Cancer Care Manitoba, Winnipeg, MB</wicri:regionArea>
<wicri:noRegion>MB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feng, Shibao" sort="Feng, Shibao" uniqKey="Feng S" first="Shibao" last="Feng">Shibao Feng</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zahlten Kumeli, Anita" sort="Zahlten Kumeli, Anita" uniqKey="Zahlten Kumeli A" first="Anita" last="Zahlten-Kumeli">Anita Zahlten-Kumeli</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kimball, Amy S" sort="Kimball, Amy S" uniqKey="Kimball A" first="Amy S" last="Kimball">Amy S. Kimball</name>
<affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amgen Inc, Thousand Oaks, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name>
<affiliation wicri:level="3"><nlm:affiliation>Hematology Department, University of Nantes, Nantes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hematology Department, University of Nantes, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Lancet. Oncology</title>
<idno type="eISSN">1474-5488</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Bortezomib (administration & dosage)</term>
<term>Bortezomib (adverse effects)</term>
<term>Cause of Death</term>
<term>Dexamethasone (administration & dosage)</term>
<term>Dexamethasone (adverse effects)</term>
<term>Disease-Free Survival</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Internationality</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Maximum Tolerated Dose</term>
<term>Middle Aged</term>
<term>Multiple Myeloma (drug therapy)</term>
<term>Multiple Myeloma (mortality)</term>
<term>Multiple Myeloma (pathology)</term>
<term>Neoplasm Recurrence, Local (drug therapy)</term>
<term>Neoplasm Recurrence, Local (mortality)</term>
<term>Neoplasm Recurrence, Local (pathology)</term>
<term>Oligopeptides (administration & dosage)</term>
<term>Oligopeptides (adverse effects)</term>
<term>Prognosis</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Bortézomib (administration et posologie)</term>
<term>Bortézomib (effets indésirables)</term>
<term>Calendrier d'administration des médicaments</term>
<term>Cause de décès</term>
<term>Dexaméthasone (administration et posologie)</term>
<term>Dexaméthasone (effets indésirables)</term>
<term>Dose maximale tolérée</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Humains</term>
<term>Internationalité</term>
<term>Modèles de hasards proportionnels</term>
<term>Myélome multiple (anatomopathologie)</term>
<term>Myélome multiple (mortalité)</term>
<term>Myélome multiple (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Oligopeptides (administration et posologie)</term>
<term>Oligopeptides (effets indésirables)</term>
<term>Perfusions veineuses</term>
<term>Pronostic</term>
<term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Relation dose-effet des médicaments</term>
<term>Récidive tumorale locale (anatomopathologie)</term>
<term>Récidive tumorale locale (mortalité)</term>
<term>Récidive tumorale locale (traitement médicamenteux)</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Survie sans rechute</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bortezomib</term>
<term>Dexamethasone</term>
<term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Bortézomib</term>
<term>Dexaméthasone</term>
<term>Oligopeptides</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Bortezomib</term>
<term>Dexamethasone</term>
<term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Myélome multiple</term>
<term>Récidive tumorale locale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Bortézomib</term>
<term>Dexaméthasone</term>
<term>Oligopeptides</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Multiple Myeloma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Myélome multiple</term>
<term>Récidive tumorale locale</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple Myeloma</term>
<term>Neoplasm Recurrence, Local</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myélome multiple</term>
<term>Récidive tumorale locale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cause of Death</term>
<term>Disease-Free Survival</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Internationality</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Maximum Tolerated Dose</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Calendrier d'administration des médicaments</term>
<term>Cause de décès</term>
<term>Dose maximale tolérée</term>
<term>Estimation de Kaplan-Meier</term>
<term>Femelle</term>
<term>Humains</term>
<term>Internationalité</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Perfusions veineuses</term>
<term>Pronostic</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
<term>Survie sans rechute</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Autriche</li>
<li>Brésil</li>
<li>Canada</li>
<li>Espagne</li>
<li>France</li>
<li>Grèce</li>
<li>République tchèque</li>
<li>Singapour</li>
<li>États-Unis</li>
</country>
<region><li>Attique (région)</li>
<li>Bade-Wurtemberg</li>
<li>Californie</li>
<li>Catalogne</li>
<li>District de Karlsruhe</li>
<li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
<li>Pays de la Loire</li>
<li>Texas</li>
<li>Vienne (Autriche)</li>
<li>État de New York</li>
<li>État de São Paulo</li>
</region>
<settlement><li>Athènes</li>
<li>Barcelone</li>
<li>Heidelberg</li>
<li>Lille</li>
<li>Nantes</li>
<li>São Paulo</li>
<li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Grèce"><region name="Attique (région)"><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name>
</region>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name>
</region>
<name sortKey="Weisel, Katja" sort="Weisel, Katja" uniqKey="Weisel K" first="Katja" last="Weisel">Katja Weisel</name>
</country>
<country name="États-Unis"><region name="État de New York"><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name>
</region>
<name sortKey="Feng, Shibao" sort="Feng, Shibao" uniqKey="Feng S" first="Shibao" last="Feng">Shibao Feng</name>
<name sortKey="Kimball, Amy S" sort="Kimball, Amy S" uniqKey="Kimball A" first="Amy S" last="Kimball">Amy S. Kimball</name>
<name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z" last="Orlowski">Robert Z. Orlowski</name>
<name sortKey="Zahlten Kumeli, Anita" sort="Zahlten Kumeli, Anita" uniqKey="Zahlten Kumeli A" first="Anita" last="Zahlten-Kumeli">Anita Zahlten-Kumeli</name>
</country>
<country name="Australie"><noRegion><name sortKey="Joshua, Douglas" sort="Joshua, Douglas" uniqKey="Joshua D" first="Douglas" last="Joshua">Douglas Joshua</name>
</noRegion>
</country>
<country name="Singapour"><noRegion><name sortKey="Chng, Wee Joo" sort="Chng, Wee Joo" uniqKey="Chng W" first="Wee-Joo" last="Chng">Wee-Joo Chng</name>
</noRegion>
</country>
<country name="Espagne"><region name="Catalogne"><name sortKey="Oriol, Albert" sort="Oriol, Albert" uniqKey="Oriol A" first="Albert" last="Oriol">Albert Oriol</name>
</region>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name>
</region>
</country>
<country name="France"><region name="Hauts-de-France"><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name>
</region>
<name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name>
</country>
<country name="République tchèque"><noRegion><name sortKey="Hajek, Roman" sort="Hajek, Roman" uniqKey="Hajek R" first="Roman" last="Hajek">Roman Hajek</name>
</noRegion>
</country>
<country name="Brésil"><region name="État de São Paulo"><name sortKey="Hungria, Vania" sort="Hungria, Vania" uniqKey="Hungria V" first="Vania" last="Hungria">Vania Hungria</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Minuk, Leonard" sort="Minuk, Leonard" uniqKey="Minuk L" first="Leonard" last="Minuk">Leonard Minuk</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001042 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001042 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28843768
   |texte=   Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28843768" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.